Abbott Laboratories
ABT
$113.61
-$0.51-0.45%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.78B | 1.64B | 1.78B | 1.33B | 9.23B |
| Total Depreciation and Amortization | 792.00M | 791.00M | 777.00M | 756.00M | 807.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 178.00M | 120.00M | 142.00M | 289.00M | 593.00M |
| Change in Net Operating Assets | 569.00M | 232.00M | -651.00M | -953.00M | -7.76B |
| Cash from Operations | 3.32B | 2.79B | 2.05B | 1.42B | 2.87B |
| Capital Expenditure | -689.00M | -496.00M | -502.00M | -484.00M | -720.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -20.00M | -55.00M | -30.00M | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -204.00M | 94.00M | -50.00M | 14.00M | -146.00M |
| Cash from Investing | -913.00M | -457.00M | -582.00M | -470.00M | -866.00M |
| Total Debt Issued | 2.00M | 0.00 | 2.00M | 1.00M | 1.00M |
| Total Debt Repaid | -72.00M | -493.00M | -17.00M | -1.04B | -614.00M |
| Issuance of Common Stock | 5.00M | 69.00M | 35.00M | 287.00M | 25.00M |
| Repurchase of Common Stock | -302.00M | -305.00M | -6.00M | -280.00M | -315.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.03B | -1.03B | -1.03B | -1.03B | -958.00M |
| Other Financing Activities | 0.00 | 0.00 | -82.00M | -- | -- |
| Cash from Financing | -1.40B | -1.76B | -1.10B | -2.06B | -1.86B |
| Foreign Exchange rate Adjustments | 6.00M | -10.00M | 51.00M | 24.00M | -83.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.01B | 560.00M | 419.00M | -1.08B | 58.00M |